Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Table 1 Patient baseline demographic and clinical characteristics

Covariate	Infants < 2 years n = 2		Children 2 to < 12 years n = 29		Adolescents 12 to < 18 years n = 38		Young adults ≥ 18 years n = 18
Covariate	n (%)	Median (min–max)	n (%)	Median (min–max)	n (%)	Median (min–max)	n (%)	Median (min–max)
Age, years	2	1 (0.6–1.5)	29	7 (2–11)	38	15 (12–17)	18	22 (18–29)
Body weight, kg	2	9.1 (8.7–9.5)	29	22.5 (12.0–74.4)	38	51.1 (28.2–105)	18	61.0 (46.2–154)
Albumin, g/L	2	33 (30–35)	28^a	41 (23–46)	38	41 (29–49)	18	39 (27–47)
Tumor burden, mm	2	59 (35–83)	23^b	55 (15–301)	28^d	78 (11–208)	15^e	120 (10–258)
Female	1 (50)	–	14 (48)	–	16 (42)	–	9 (50)	–
ADA positive	0 (0)^a	–	5 (17)^c	–	4 (11)^e	–	2 (11)^a	–
No. of tumor types present	2	1	29	12	38	15	18	10
Lansky/Karnofsky PS	2	90 (90–90)	29	100 (60–100)	38	90 (70–100)	18	95 (70–100)

Abbreviations: ADA Anti-drug antibodies, PS Performance status
^an = 1, ^bn = 6, ^cn = 5, ^dn = 10, ^en = 3 missing covariates were imputed to the median value